GeneDx price target raised to $170 from $115 at Guggenheim

Guggenheim raised the firm’s price target on GeneDx (WGS) to $170 from $115 and keeps a Buy rating on the shares following what the firm calls out as another quarter of whole exome and genome growth, strong average selling prices, and gross margin improvements. With “a large beat and even larger guidance raise,” the firm does not believe management intended to signal a move to negative EPS despite management’s comments on 2026 operating expenses, the analyst added.